BP
PRCT icon

Ballentine Partners’s Procept Biorobotics PRCT Stock Holding History

Ballentine Partners’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-133,000
Closed -$5.57M – 756
2023
Q4 		$5.57M Buy
+133,000
New +$4.53M 0.11% 68

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ballentine Partners's PRCT Position: Q1 2024 in Review

Ballentine Partners sold out of Procept Biorobotics (PRCT) in Q1 2024, closing a stake of 133,000 shares — an estimated $5.57M sold.

Ballentine Partners first reported a position in PRCT in Q4 2023 and held it in 1 quarter. The position peaked at $5.57M in Q4 2023. 162 funds tracked by Wall St. Rank hold PRCT as of Q1 2024.

  • Ballentine Partners reported no remaining Procept Biorobotics position as of Q1 2024 after selling out during the quarter.
  • Ballentine Partners sold 133,000 Procept Biorobotics shares in Q1 2024, an estimated $5.57M.
  • Ballentine Partners first reported a position in Procept Biorobotics in Q4 2023 and held it in 1 quarter.
  • Ballentine Partners's Procept Biorobotics position peaked at $5.57M in Q4 2023.
  • 162 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2024.

Based on Ballentine Partners's 13F filing for Q1 2024, filed 11 Apr 2024.